Naturmega Advances Ruby-O® Clinical Program with Newly Registered Trial

As part of its structured clinical roadmap for Ruby-O®, Naturmega continues to build the scientific foundation behind its next-generation phospholipid omega-3 technology. Following the publication of its first clinical study earlier this year, the company is expanding its research program through new human investigations designed to further characterize the performance of bonded phospholipid omega-3 delivery across multiple health applications.

KEY STUDY PARAMETERS

24 weeks

Intervention duration

100+ participants

Expected enrollment

Double-blind RCT

Randomized, controlled design

This registration marks another milestone in the scientific development of the Ruby-O® platform and reflects Naturmega’s broader commitment to advancing next-generation omega-3 delivery systems.

One of these studies is now officially registered on ClinicalTrials.gov. The randomized, double-blind trial will evaluate Ruby-O® phospholipid omega-3 versus conventional formulations in adults with mixed dyslipidemia, examining omega-3 incorporation, metabolic markers, and cardiovascular outcomes over a 24-week intervention. Enrollment is expected to exceed 100 participants.

2026 SCIENTIFIC ROADMAP

Beyond this trial, additional clinical investigations are already planned as part of the 2026 Ruby-O® scientific roadmap, reinforcing the company’s long-term investment in differentiated lipid technologies and evidence-based innovation.

Because the future of omega-3 is not only about concentration. It is about design, delivery, and performance.